Search Results for "Lazanda"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Lazanda. Results 1 to 4 of 4 total matches.
See also: fentanyl

Fentanyl Nasal Spray (Lazanda) for Pain

   
The Medical Letter on Drugs and Therapeutics • Dec 12, 2011  (Issue 1379)
Fentanyl Nasal Spray (Lazanda) for Pain ...
The FDA has approved a nasal spray formulation of fentanyl (Lazanda – Archimedes) for management of breakthrough pain in adult cancer patients who are already receiving and are tolerant to opioid therapy. Fentanyl is already available in the US for intravenous, intrathecal, epidural, transdermal and oral transmucosal use.
Med Lett Drugs Ther. 2011 Dec 12;53(1379):99-100 |  Show IntroductionHide Introduction

Fentanyl Sublingual Spray (Subsys) for Breakthrough Cancer Pain

   
The Medical Letter on Drugs and Therapeutics • May 14, 2012  (Issue 1390)
Onsolis (Meda) 200, 400, 600, 20.58 800, 1200 mcg Intranasal spray Lazanda (Archimedes) 100 mcg/100 mcL ...
The FDA has approved a sublingual spray formulation of fentanyl (Subsys – Insys) for management of breakthrough pain in adult cancer patients who are receiving and are tolerant to opioid therapy (taking ≥60 mg/day of oral morphine or the equivalent). Fentanyl is already available in the US for intravenous, intrathecal, epidural, transdermal and transmucosal use.
Med Lett Drugs Ther. 2012 May 14;54(1390):39-40 |  Show IntroductionHide Introduction

Comparison Table: Some Oral/Transdermal Opioid Analgesics (online only)

   
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022  (Issue 1665)
for opioid-naive patients Actiq, Fentora, Lazanda, and Subsys are indicated only for breakthrough pain ...
View the Comparison Table: Some Oral/Transdermal Opioid Analgesics
Med Lett Drugs Ther. 2022 Dec 12;64(1665):e199-202 |  Show IntroductionHide Introduction

Opioids for Pain

   
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022  (Issue 1665)
Not recommended for opioid-naive patients Actiq, Fentora, Lazanda, and Subsys are indicated only ...
A new CDC guideline for prescribing opioids for pain recently became available. Nonopioid drugs for pain were reviewed in a previous issue.
Med Lett Drugs Ther. 2022 Dec 12;64(1665):193-200 |  Show IntroductionHide Introduction